ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 374

Anxiolytic Effects of the Novel α2δ Ligand Mirogabalin (DS-5565) in Sluka Model, an Experimental Animal Model of Fibromyalgia

Yuki Domon1, Naohisa Arakawa1, Hiroyasu Murasawa2, Hiroyuki Kobayashi2, Kensuke Saeki2 and Yutaka Kitano1, 1Pain & Neuroscience Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan, 2Nihon Bioresearch Inc., Hashima, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: analgesics, Animal models, Anxiety and fibromyalgia

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 13, 2016

Session Title: Pain – Basic and Clinical Aspects - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Anxiolytic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Sluka Model, an Experimental Animal Model of Fibromyalgia Yuki Domona, Naohisa Arakawaa, Hiroyasu Murasawab, Hiroyuki Kobayashib, Kensuke Saekib, Yutaka Kitanoa a Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan b Hashima Laboratory, Nihon Bioresearch Inc., Gifu, Japan

Background/Purpose: Mirogabalin (DS-5565) is a novel ligand of the alpha-2-delta subunit of voltage-gated calcium channels. Mirogabalin possesses unique binding characteristics to alpha-2-delta subunits, and potent and long-lasting analgesic effects in fibromyalgia models and neuropathic pain models. Phase III clinical trials of mirogabalin in patients with fibromyalgia, diabetic peripheral neuropathic pain and postherpetic neuralgia are ongoing. Fibromyalgia is often associated with anxiety and depressive symptoms. In the present study, we investigated the anxiolytic effects of mirogabalin in intramuscular acidic saline injection model (Sluka model) in rats, an experimental animal model for fibromyalgia.

Methods: Male SD rats received two repeated intramuscular injections of acidic saline (pH 4.0) into the gastrocnemius muscle. After development of hyperalgesia, the animals received the test compound orally and the anxiolytic effects were determined in open field test and elevated plus maze test at 2 h after administration. Dose levels of mirogabalin were set at 3 and 10 mg/kg, and the normal and model control groups received vehicle (distilled water).

Results: Sluka model rats showed mechanical hyperalgesia demonstrated by decreased pain thresholds to von Frey filaments. In the open filed test, Sluka model rats significantly preferred the wall-area to the central-area compared with normal rats. In the elevated plus maze test, Sluka model rats exhibited significant decreases in the number of entries and time spent in the open-arm, and significant increases in time spent in the closed-arm. Taken together, Sluka model rats showed anxiety-related behaviors. A single oral administration of mirogabalin (3 and 10 mg/kg) significantly alleviated and normalized above anxiety-related behaviors in both tests.

Conclusion: Sluka model rats showed anxiety-related behaviors in open field test and elevated plus maze test. Mirogabalin alleviated the anxiety-related behaviors in Sluka model rats. Mirogabalin may provide effective anxiety relief for patients with fibromyalgia, as well as pain relief.

Figure 1 Effects of mirogabalin on anxiety-like behavior in open-field test in Sluka model rats.

Figure 2 Effects of mirogabalin on anxiety-like behavior in elevated plus maze test in Sluka model rats.


Disclosure: Y. Domon, Daiichi Sankyo Co., Ltd., 3; N. Arakawa, Daiichi Sankyo Co., Ltd., 3; H. Murasawa, Daiichi Sankyo Co., Ltd., 5; H. Kobayashi, Daiichi Sankyo Co., Ltd, 5; K. Saeki, Daiichi Sankyo Co.,Ltd., 5; Y. Kitano, Daiichi Sankyo Co., Ltd., 3.

To cite this abstract in AMA style:

Domon Y, Arakawa N, Murasawa H, Kobayashi H, Saeki K, Kitano Y. Anxiolytic Effects of the Novel α2δ Ligand Mirogabalin (DS-5565) in Sluka Model, an Experimental Animal Model of Fibromyalgia [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/anxiolytic-effects-of-the-novel-%ce%b12%ce%b4-ligand-mirogabalin-ds-5565-in-sluka-model-an-experimental-animal-model-of-fibromyalgia/. Accessed March 1, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anxiolytic-effects-of-the-novel-%ce%b12%ce%b4-ligand-mirogabalin-ds-5565-in-sluka-model-an-experimental-animal-model-of-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.